We see an updated power point with the 3 patients efficacy data, announcement of new dosing groups next week IMO.
It sure seems like they dosed 3 patients, realized the efficacy at the low dose was something special, and made moves to go public.
However, if next week Redman trots out the same old powerpoint, and we just get announcements of a new scientific advisory committee member once every couple of months it's gonna be sad.
I wouldn't be surprised by either. My gut tells me they have something, but I also wouldn't be surprised to not see any phase 1 hard data till May.
BUT if you have ANYTHING--now is the time. Filings say they need 2 million to finish phase 1.
IMO. GLTU.
